Fig. 4.

Targeting the immune functions of tenascin-C in cancer. (A) Summarized here are approaches for targeting the diverse functions of TNC in immunity that could be used to improve the anti-tumor immune surveillance phenotype. (B) Targeting ‘TIL-matrix retention’ represents a novel opportunity to target TNC in cancer, potentially abolishing the immune-exclusion phenotype and empowering immune checkpoint therapies that do not require the lowering of TNC expression, offering the opportunity to potentially preserve its desirable DAMP actions.